90 filings
8-K
NNMX
NANOMIX Corp
24 Nov 23
Departure of Directors or Certain Officers
4:20pm
8-K
NNMX
NANOMIX Corp
10 Mar 23
Regulation FD Disclosure
4:04pm
8-K
NNMX
NANOMIX Corp
25 Jan 23
Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer
4:43pm
8-K
NNMX
NANOMIX Corp
10 Nov 22
Unregistered Sales of Equity Securities
8:35am
8-K
NNMX
NANOMIX Corp
9 Sep 22
Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors
4:23pm
8-K
pwka4a2j
29 Jul 22
Nanomix Announces Appoints Life Sciences Executive Thomas Schlumpberger as Chief Executive Officer and Member of the Board of Directors
3:57pm
8-K
c5xhit8kbqum p2
10 May 22
Nanomix Appoints Vidur Sahney as Chief Operating Officer
4:06pm
8-K
58jbsb9f9 65cxgvmrh
24 Mar 22
Entry into a Material Definitive Agreement
9:13am
8-K
ouiqh74v
2 Mar 22
Nanomix Completes 1-for-173 Reverse Stock Split
5:27pm
8-K
8gih8 zoi
1 Mar 22
Entry into a Material Definitive Agreement
8:58am
8-K
9mq emaidp1ymx52a
17 Nov 21
Other Events
12:00am
8-K
9nf8n m28910imz6x8
5 Nov 21
Regulation FD Disclosure
5:06pm
8-K/A
ozqwrn01skg8
5 Nov 21
Other Events
4:47pm
8-K
cooola qw3q
10 Sep 21
Amendments to Articles of Incorporation or Bylaws
2:05pm
8-K/A
uscfcme
27 Aug 21
Management’s Discussion and Analysis of Financial Condition and Results of Operations
12:00am
8-K
3v2hvft5te
29 Jun 21
Boston Therapeutics Announces $8.4 Million Convertible Placement
9:06am
8-K
k70 mhicdl858
10 Jun 21
Entry into a Material Definitive Agreement
5:00pm
8-K
m2bp 0gezhawd
12 May 21
Entry into a Material Definitive Agreement
5:08pm
8-K
o0cxna9rvj4
2 Feb 21
Entry into a Material Definitive Agreement
5:00pm
8-K
sm9ik0ectd5
15 May 20
Other Events
4:54pm